Following a dinner with management, Jefferies analyst Matthew Andrews calls shares of TherapeuticsMD undervalued. TX-004HR is a differentiated novel estrogen drug while TX-001HR is a potential new "gold standard" in vasomotor symptoms, Andrews tells investors in a research note partially titled "2018 to Bring Innovation Back to Women's Health." With new drug applications for both under FDA review, TherapeuticsMD is on track for two approvals in 2018, a "rare biopharma achievement," in the multi-billion vaginal atrophy and vasomotor symptoms markets, the analyst writes. He keeps a Buy rating on TherapeuticsMD with a $15 price target.